Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer

July 25, 2014

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading.

One pioneering approach, discussed in a review article published this week in WIREs Nanomedicine and Nanobiotechnology, uses to jumpstart the body's ability to fight tumors. Nanoparticles are too small to imagine. One billion could fit on the head of a pin. This makes them stealthy enough to penetrate cancer cells with therapeutic agents such as antibodies, drugs, vaccine type viruses, or even metallic particles. Though small, nanoparticles can pack large payloads of a variety of agents that have different effects that activate and strengthen the body's immune system response against tumors.

There is an expanding array of nanoparticle types being developed and tested for cancer therapy. They are primarily being used to package and deliver the current generation of cancer cell killing drugs and progress is being made in that effort.

" Our lab's approach differs from most in that we use nanoparticles to stimulate the immune system to attack tumors and there are a variety of potential ways that can be done," said Steve Fiering, PhD, Norris Cotton Cancer Center researcher and professor of Microbiology and Immunology, and of Genetics at the Geisel School of Medicine at Dartmouth. "Perhaps the most exciting potential of nanoparticles is that although very small, they can combine multiple ."

The immune therapy methods limit a tumor's ability to trick the immune system. It helps it to recognize the threat and equip it to effectively attack the tumor with more "soldier" cells. These approaches are still early in development in the laboratory or clinical trials.

"Now that efforts to stimulate anti-tumor immune responses are moving from the lab to the clinic, the potential for nanoparticles to be utilized to improve an immune-based therapy approach is attracting a lot of attention from both scientists and clinicians. And clinical usage does not appear too distant," said Fiering.

Fiering is testing the use of heat in combination with nanoparticles. An inactive metallic nanoparticle containing iron, silver, or gold is absorbed by a cancer cell. Then the nanoparticle is activated using magnetic energy, infrared light, or radio waves. The interaction creates heat that kills cancer cells. The heat, when precisely applied, can prompt the immune system to kill that have not been heated. The key to this approach is minimizing healthy tissue damage while maximizing cancerous tumor destruction of the sort that improves recognition of the tumor by the immune system.

Fiering cautions that there is a great deal of research and many technical variables that should be explored to find the most effective ways to use nanoparticles to heat tumors and stimulate anti-tumor immunity.

According to Fiering, this approach is far from new, "The use of heat to treat cancer was first recorded by ancient Egyptians. But has reemerged with high tech modern systems as a contributor to the new paradigm of fighting cancer with the patients' own ."

Explore further: Researchers find promising results with local hyperthermia of tumors

Related Stories

Researchers find promising results with local hyperthermia of tumors

March 4, 2014
A combination of iron-oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth-Hitchcock ...

The immune system's redesigned role in fighting cancerous tumors

March 12, 2014
Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune ...

Toxoplasma gondii can stop cancer in its tracks as a vaccine

July 18, 2014
Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat's intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world's population, 60 ...

Vaccine 'reprograms' pancreatic cancers to respond to immunotherapy

June 18, 2014
Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.